{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:12:30Z","timestamp":1783923150060,"version":"3.55.0"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430114"],"award-info":[{"award-number":["82430114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2025xkjT013"],"award-info":[{"award-number":["2025xkjT013"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2308085MH311"],"award-info":[{"award-number":["2308085MH311"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118144","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:18:32Z","timestamp":1780589912000},"page":"118144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Research progress on drug resistance mechanisms and therapeutic strategies for difficult-to-treat rheumatoid arthritis"],"prefix":"10.1016","volume":"251","author":[{"given":"Xinling","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1600-0024","authenticated-orcid":false,"given":"Yujing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118144_b0005","doi-asserted-by":"crossref","unstructured":"A. Di Matteo, J.M. Bathon, P. Emery, Rheumatoid arthritis, Lancet (London, England) 402(10416) (2023) 2019-2033.","DOI":"10.1016\/S0140-6736(23)01525-8"},{"issue":"12","key":"10.1016\/j.bcp.2026.118144_b0010","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","article-title":"Signaling pathways in rheumatoid arthritis: implications for targeted therapy","volume":"8","author":"Ding","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.101477","article-title":"The epidemiology of established rheumatoid arthritis","volume":"33","author":"Ot\u00f3n","year":"2019","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"26","key":"10.1016\/j.bcp.2026.118144_b0025","first-page":"00075","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update","volume":"S0003\u20134967","author":"Smolen","year":"2026","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.bcp.2026.118144_b0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-020-01309-9","article-title":"Understanding refractory rheumatoid arthritis: implications for a therapeutic approach","volume":"80","author":"Melville","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","article-title":"Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis","volume":"17","author":"Buch","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0045","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10787-020-00741-3","article-title":"The advances of methotrexate resistance in rheumatoid arthritis","volume":"28","author":"Yu","year":"2020","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2026.118144_b0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","article-title":"Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice","volume":"55","author":"Schaeverbeke","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.bcp.2026.118144_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113074","article-title":"Application and pharmacological mechanism of methotrexate in rheumatoid arthritis","volume":"150","author":"Zhao","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bcp.2026.118144_b0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118144_b0070","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/jcph.70039","article-title":"Can methotrexate monotherapy achieve clinical remission in patients with active rheumatoid arthritis? A model-based meta-analysis","volume":"65","author":"Chen","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118144_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113558","article-title":"OAT3 mediates methotrexate resistance in the treatment of rheumatoid arthritis","volume":"153","author":"Gao","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118144_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113067","article-title":"Glycolysis aggravates methotrexate toxicity by fueling RFC1-controlled intestinal absorption in rheumatic rats","volume":"150","author":"Wang","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0085","doi-asserted-by":"crossref","DOI":"10.4238\/gmr.15027927","article-title":"Overexpression of P-glycoprotein on fibroblast-like synoviocytes in refractory rheumatoid arthritis patients: a potential mechanism for multidrug resistance in rheumatoid arthritis treatment","volume":"15","author":"Liu","year":"2016","journal-title":"Genet. Mol. Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5493\/wjem.v5.i4.225","article-title":"Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis","volume":"5","author":"Tsujimura","year":"2015","journal-title":"World J. Exp. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0095","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s11010-022-04354-y","article-title":"Research advances in the role and pharmaceuticals of ATP-binding cassette transporters in autoimmune diseases","volume":"477","author":"Yu","year":"2022","journal-title":"Mol. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0100","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10787-018-0529-2","article-title":"Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis","volume":"26","author":"Perez-Guerrero","year":"2018","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2026.118144_b0105","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/art.24354","article-title":"Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide","volume":"60","author":"van der Heijden","year":"2009","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0110","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/ard.2003.014985","article-title":"Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis","volume":"64","author":"Wolf","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.bcp.2026.118144_b0115","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3390\/ph14101036","article-title":"Folium sennae increased the bioavailability of methotrexate through modulation on MRP 2 and BCRP","volume":"14","author":"Yu","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00018-025-05707-8","article-title":"Single-cell multi-dimensional data analysis decodes RNF19A-mediated drug resistance in rheumatoid arthritis fibroblast-like synoviocytes: mechanisms and biological insights","volume":"82","author":"Luo","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"issue":"8","key":"10.1016\/j.bcp.2026.118144_b0125","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.1424792112","article-title":"Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis","volume":"112","author":"Peres","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2026.118144_b0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaut.2018.01.004","article-title":"TGF-\u03b2 signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis","volume":"90","author":"Peres","year":"2018","journal-title":"J. Autoimmun."},{"issue":"7","key":"10.1016\/j.bcp.2026.118144_b0135","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/art.41223","article-title":"Association of a type 2\u2013polarized T cell phenotype with methotrexate nonresponse in patients with rheumatoid arthritis","volume":"72","author":"Slauenwhite","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0140","first-page":"3728","article-title":"Dysregulated ICOS+ proinflammatory and suppressive regulatory T cells in patients with rheumatoid arthritis","volume":"16","author":"Wang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2026.118144_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157731","article-title":"Paeoniflorin derivative ameliorates methotrexate resistance in treating rheumatoid arthritis through targeting GRK2-A2AAR axis","volume":"150","author":"Guo","year":"2026","journal-title":"Phytomedicine"},{"issue":"7","key":"10.1016\/j.bcp.2026.118144_b0150","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/art.1780330706","article-title":"The in vitro effects of methotrexate on peripheral blood mononuclear cells: Modulation by methyl donors and spermidine","volume":"33","author":"Nesher","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"7","key":"10.1016\/j.bcp.2026.118144_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102084","article-title":"mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine","volume":"298","author":"Alam","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-019-1936-5","article-title":"Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients","volume":"21","author":"Gosselt","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0165","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.39031","article-title":"Methotrexate restores regulatory T cell function through demethylation of the FoxP3 Upstream enhancer in patients with rheumatoid arthritis","volume":"67","author":"Cribbs","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101756","article-title":"The naturally occurring flavonoid nobiletin reverses methotrexate resistance via inhibition of P-glycoprotein synthesis","volume":"298","author":"Liu","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.bcp.2026.118144_b0175","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.3390\/jcm14186409","article-title":"Pathogenic role of cytokines in rheumatoid arthritis","volume":"14","author":"Fujimoto","year":"2025","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.118144_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102398","article-title":"Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents","volume":"18","author":"Rubbert-Roth","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2026.118144_b0185","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3389\/fimmu.2020.00589","article-title":"What is the clinical relevance of TNF inhibitor immunogenicity in the management of patients with rheumatoid arthritis?","volume":"11","author":"Mehta","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118144_b0190","article-title":"Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity","volume":"15","author":"Siegel","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118144_b0195","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.3390\/jcm12093271","article-title":"Anti-drug antibodies in the biological therapy of autoimmune rheumatic diseases","volume":"12","author":"Pizano-Martinez","year":"2023","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0200","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2026.118144_b0205","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cellimm.2015.03.002","article-title":"Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products","volume":"295","author":"Yin","year":"2015","journal-title":"Cell. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0215","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0220","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11095-011-0414-9","article-title":"Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions","volume":"28","author":"Kumar","year":"2011","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tips.2009.11.001","article-title":"Immunological mechanism underlying the immune response to recombinant human protein therapeutics","volume":"31","author":"Sauerborn","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118144_b0230","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.23098","article-title":"Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies","volume":"6","author":"Bitoun","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0235","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.bcp.2026.118144_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148607","article-title":"Emerging trends and therapeutic applications of monoclonal antibodies","volume":"925","author":"Mekala","year":"2024","journal-title":"Gene"},{"key":"10.1016\/j.bcp.2026.118144_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.782788","article-title":"Immune complex formation is associated with loss of tolerance and an antibody response to both drug and target","volume":"12","author":"Kroenke","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118144_b0250","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics \u2013 the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118144_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.bcp.2026.118144_b0260","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tips.2009.04.007","article-title":"Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action","volume":"30","author":"Jefferis","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2017","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0270","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40744-022-00464-7","article-title":"Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: results from a Norwegian cross-sectional observational study","volume":"9","author":"Michelsen","year":"2022","journal-title":"Rheumatol. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2026.118144_b0275","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.bcp.2026.118144_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1377911","article-title":"Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis","volume":"15","author":"Sugiyama","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118144_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.885672","article-title":"Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients","volume":"13","author":"Mosch","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118144_b0290","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/art.24709","article-title":"Anti\u2010adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin\u201010 gene polymorphisms","volume":"60","author":"Bartelds","year":"2009","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.bcp.2026.118144_b0295","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fimmu.2020.01301","article-title":"T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation\u2013updated consensus and review 2020","volume":"11","author":"Jawa","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118144_b0300","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118144_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1677925","article-title":"Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk","volume":"16","author":"Rose","year":"2025","journal-title":"Front. Immunol."},{"issue":"S3","key":"10.1016\/j.bcp.2026.118144_b0310","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1002\/jcph.380","article-title":"Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety","volume":"55","author":"Xu","year":"2015","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118144_b0315","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2018-213403","article-title":"Methotrexate and BAFF interaction prevents immunization against TNF inhibitors","volume":"77","author":"Bitoun","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2026.118144_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2025.1432935","article-title":"Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis","volume":"5","author":"Chen","year":"2025","journal-title":"Front. Ophthalmol."},{"key":"10.1016\/j.bcp.2026.118144_b0325","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2015.00109","article-title":"Immunogenicity of anti-TNF-\u03b1 biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection","volume":"6","author":"Bendtzen","year":"2015","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118144_b0330","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/ard.2009.117309","article-title":"Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF\u03baB signalling pathways","volume":"69","author":"Potter","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0335","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/bcp.15658","article-title":"Assessment of the influence of Fc\u2010\u03b3 receptor polymorphisms on biologics' pharmacokinetics in Tunisian rheumatoid arthritis patients","volume":"89","author":"Mahmoud","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118144_b0340","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2015-208001","article-title":"Increased pretreatment serum IFN-\u03b2\/\u03b1 ratio predicts non-response to tumour necrosis factor \u03b1 inhibition in rheumatoid arthritis","volume":"75","author":"Wampler Muskardin","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2026.118144_b0345","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/rheumatology\/ker338","article-title":"Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy","volume":"51","author":"Wright","year":"2011","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0350","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/ar3431","article-title":"Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy","volume":"13","author":"Chen","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0355","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2026.118144_b0360","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0365","doi-asserted-by":"crossref","first-page":"9736","DOI":"10.1038\/s41598-025-94894-2","article-title":"Comparison of anti-inflammatory and anti-angiogenic effects of JAK inhibitors in IL-6 and TNF\u03b1-stimulated fibroblast-like synoviocytes derived from patients with RA","volume":"15","author":"Suda","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118144_b0370","doi-asserted-by":"crossref","first-page":"10953","DOI":"10.2147\/JIR.S530754","article-title":"Role of interleukin-6 in rheumatoid arthritis-associated interstitial lung disease: focus on the JAK\/STAT pathway and macrophage polarization","volume":"18","author":"Yu","year":"2025","journal-title":"J. Inflamm. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0375","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41590-022-01387-9","article-title":"TH17 cell heterogeneity and its role in tissue inflammation","volume":"24","author":"Schnell","year":"2023","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0380","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41413-024-00342-8","article-title":"Wnt\/\u03b2-catenin signaling components and mechanisms in bone formation, homeostasis, and disease","volume":"12","author":"Hu","year":"2024","journal-title":"Bone Res."},{"key":"10.1016\/j.bcp.2026.118144_b0390","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.intimp.2018.12.050","article-title":"Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators","volume":"67","author":"Fassio","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118144_b0395","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3389\/fimmu.2020.00845","article-title":"A pauci-immune synovial pathotype predicts inadequate response to TNF\u03b1-blockade in rheumatoid arthritis patients","volume":"11","author":"Nerviani","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0400","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00296-019-04276-x","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-\u03b1 agents in patients with rheumatoid arthritis: a retrospective chart review analysis","volume":"39","author":"Lee","year":"2019","journal-title":"Rheumatol. Int."},{"issue":"11","key":"10.1016\/j.bcp.2026.118144_b0405","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/art.24913","article-title":"The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study","volume":"60","author":"Klaasen","year":"2009","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0410","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.3390\/ijms23042366","article-title":"Pharmacogenomics of anti-TNF treatment response marks a new era of tailored rheumatoid arthritis therapy","volume":"23","author":"Wysocki","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.bcp.2026.118144_b0415","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1074\/jbc.RA118.005828","article-title":"Insights into ligand binding by a viral tumor necrosis factor (TNF) decoy receptor yield a selective soluble human type 2 TNF receptor","volume":"294","author":"Pontejo","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118144_b0420","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.phrs.2016.11.025","article-title":"Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: therapeutic implications","volume":"115","author":"Szondy","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0425","doi-asserted-by":"crossref","first-page":"R219","DOI":"10.1186\/ar4416","article-title":"Deficient spontaneous apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition","volume":"15","author":"Meusch","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0430","doi-asserted-by":"crossref","first-page":"20297","DOI":"10.1038\/s41598-020-77380-9","article-title":"Chronic exposure to TNF reprograms cell signaling pathways in fibroblast-like synoviocytes by establishing long-term inflammatory memory","volume":"10","author":"Gangishetti","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0435","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-019-1818-x","article-title":"Reduction of autophagy and increase in apoptosis correlates with a favorable clinical outcome in patients with rheumatoid arthritis treated with anti-TNF drugs","volume":"21","author":"Vomero","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2026.118144_b0440","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/eji.201646375","article-title":"Increased autophagy in CD4+ T cells of rheumatoid arthritis patients results in T\u2010cell hyperactivation and apoptosis resistance","volume":"46","author":"van Loosdregt;","year":"2016","journal-title":"Eur. J. Immunol."},{"issue":"10271","key":"10.1016\/j.bcp.2026.118144_b0445","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0450","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/annrheumdis-2013-204544","article-title":"An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial","volume":"74","author":"Vital","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2026.118144_b0455","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.2147\/DDDT.S527687","article-title":"Rheumatoid arthritis therapy based on B cells","volume":"19","author":"Liang","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0460","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/annrheumdis-2013-204417","article-title":"Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy","volume":"73","author":"Das","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0465","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40620-024-02182-5","article-title":"Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a case report","volume":"38","author":"Oll\u00e9","year":"2025","journal-title":"J. Nephrol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118144_b0470","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2018-214898","article-title":"Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire","volume":"78","author":"Pollastro","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0475","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2008.092791","article-title":"Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation","volume":"68","author":"Teng","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0480","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-024-03297-7","article-title":"Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis","volume":"26","author":"Pollastro","year":"2024","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0485","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11033-025-10366-w","article-title":"Rheumatoid arthritis unmasked: the power of B cell depletion therapy","volume":"52","author":"Alghazali","year":"2025","journal-title":"Mol. Biol. Rep."},{"issue":"8","key":"10.1016\/j.bcp.2026.118144_b0490","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/art.39167","article-title":"Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2026.118144_b0495","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2021.11.004","article-title":"B cell-activating factor and its targeted therapy in autoimmune diseases","volume":"64","author":"Zhang","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0500","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF- and APRIL-targeted therapy in systemic autoimmune diseases","volume":"36","author":"Nakayamada","year":"2016","journal-title":"Inflammation Regeneration"},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0505","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41392-019-0051-z","article-title":"Therapeutic effects of a novel BAFF blocker on arthritis","volume":"4","author":"Zhou","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118144_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103326","article-title":"Regulatory B cells in autoimmune diseases: Insights and therapeutic potential","volume":"149","author":"Su","year":"2024","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118144_b0515","first-page":"1925","article-title":"Expression levels of CXCR4 and CXCL12 in patients with rheumatoid arthritis and its correlation with disease activity","volume":"20","author":"Peng","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0520","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41584-021-00601-6","article-title":"Immunological memory in rheumatic inflammation \u2014 a roadblock to tolerance induction","volume":"17","author":"Maschmeyer","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0525","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302465","article-title":"CXCR4: from B-cell development to B cell\u2013mediated diseases","volume":"7","author":"Giorgiutti","year":"2024","journal-title":"Life Sci. Alliance"},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0530","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0535","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/14397595.2017.1332507","volume":"28","author":"Ogata","year":"2017","journal-title":"Mod. Rheumatol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0540","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/14397595.2018.1533514","article-title":"Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: results from the open-label extension of the SHINOBI study","volume":"29","author":"Ogata","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118144_b0545","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14397595.2018.1486939","article-title":"The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab","volume":"29","author":"Ebina","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0550","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/14397595.2016.1206242","article-title":"Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab","volume":"27","author":"Matsuno","year":"2016","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0555","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-024-03373-y","article-title":"Serum GM-CSF level is a predictor of treatment response to tocilizumab in rheumatoid arthritis patients: a prospective observational cohort study","volume":"26","author":"Su","year":"2024","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0560","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-023-03242-0","article-title":"Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab","volume":"26","author":"Thudium","year":"2024","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-023-03236-y","article-title":"Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis","volume":"26","author":"Iwasaki","year":"2024","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2026.118144_b0570","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.bcp.2026.118144_b0575","article-title":"Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: an exploratory research","volume":"14","author":"Kuwana","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bcp.2026.118144_b0580","first-page":"1674","article-title":"Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis","volume":"40","author":"Sugawara","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0585","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/jcm15010278","article-title":"Clinical and ultrasound remission in rheumatoid arthritis patients treated with JAK inhibitors: a real-world study","volume":"15","author":"Lasa-Teja","year":"2025","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0590","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13023-017-0630-4","article-title":"Whipple\u2019s disease mimicking rheumatoid arthritis can cause misdiagnosis and treatment failure","volume":"12","author":"Glaser","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcp.2026.118144_b0595","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/annrheumdis-2016-eular.4717","article-title":"SAT0489 biologic therapies and infections in the daily practice: a study on historical cohort from 3 italian rheumatologic units","volume":"75","author":"Cipriani","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2026.118144_b0600","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241308027","article-title":"Impact of obesity on clinical outcomes and treatment continuation in rheumatoid arthritis patients receiving non-TNF-targeted therapies","volume":"16","author":"Park","year":"2024","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.bcp.2026.118144_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114890","article-title":"Multi-target RNA interference: a disruptive next-generation strategy for precision treatment of rheumatoid arthritis","volume":"159","author":"Shan","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0610","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0615","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12967-018-1387-9","article-title":"Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis","volume":"16","author":"Carini","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118144_b0620","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.trsl.2024.07.001","article-title":"A multi-biomarker panel for predicting Tocilizumab response in Rheumatoid arthritis patients","volume":"273","author":"Cho","year":"2024","journal-title":"Transl. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0625","doi-asserted-by":"crossref","first-page":"33499","DOI":"10.1038\/s41598-025-17066-2","article-title":"Epitope mapping strategies for immunogenicity mitigation in streptokinase therapeutics: an in-silico study","volume":"15","author":"Hajizade","year":"2025","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0630","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0635","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0640","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1186\/s12967-024-05569-x","article-title":"Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis","volume":"22","author":"Su","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0645","doi-asserted-by":"crossref","first-page":"20150","DOI":"10.1038\/srep20150","article-title":"A dual target-directed agent against interleukin-6 receptor and tumor necrosis factor \u03b1 ameliorates experimental arthritis","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118144_b0650","article-title":"The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2","volume":"16","author":"Yan","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118144_b0655","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1039\/D5NA00671F","article-title":"Targeted nanocarriers integrating photodynamic and photothermal therapy: a paradigm shift in rheumatoid arthritis treatment","volume":"8","author":"Priya","year":"2025","journal-title":"Nanoscale Adv."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0660","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1186\/s13063-021-05640-8","article-title":"Photodynamic therapy for synovial hyperplasia in patients with refractory rheumatoid arthritis: a study protocol for a randomized, double-blind, blank-controlled prospective trial","volume":"22","author":"Zhao","year":"2021","journal-title":"Trials"},{"issue":"28","key":"10.1016\/j.bcp.2026.118144_b0665","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020966","article-title":"Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatod arthritis","volume":"99","author":"Xing","year":"2020","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.bcp.2026.118144_b0670","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","article-title":"Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis","volume":"35","author":"Li","year":"2025","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118144_b0675","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0680","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s13287-025-04495-z","article-title":"Harnessing mesenchymal stem\/stromal cells-based therapies for rheumatoid arthritis: mechanisms, clinical applications, and microenvironmental interactions","volume":"16","author":"Gao","year":"2025","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0685","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s13287-025-04515-y","article-title":"Review: progression and heterogeneity of multiple sources of mesenchymal stromal cells for the treatment of rheumatoid arthritis","volume":"16","author":"Wu","year":"2025","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0690","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3390\/pharmaceutics14020404","article-title":"Human bone marrow mesenchymal stromal\/stem cells regulate the proinflammatory response of monocytes and myeloid dendritic cells from patients with rheumatoid arthritis","volume":"14","author":"Laranjeira","year":"2022","journal-title":"Pharmaceutics"},{"issue":"14","key":"10.1016\/j.bcp.2026.118144_b0695","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3390\/cells12141905","article-title":"Management of rheumatoid arthritis: possibilities and challenges of mesenchymal stromal\/stem cell-based therapies","volume":"12","author":"Shimizu","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0700","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"20","key":"10.1016\/j.bcp.2026.118144_b0705","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202307379","article-title":"Neutrophil\u2010mimetic, ROS responsive, and oxygen generating nanovesicles for targeted interventions of refractory rheumatoid arthritis","volume":"20","author":"Tang","year":"2023","journal-title":"Small"},{"issue":"8","key":"10.1016\/j.bcp.2026.118144_b0710","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/s41401-021-00801-6","article-title":"Novel treatment for refractory rheumatoid arthritis with total glucosides of paeony and nobiletin codelivered in a self-nanoemulsifying drug delivery system","volume":"43","author":"Qu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"11","key":"10.1016\/j.bcp.2026.118144_b0715","doi-asserted-by":"crossref","first-page":"18430","DOI":"10.1021\/acsnano.2c06584","article-title":"Engineered platelet microparticle-membrane camouflaged nanoparticles for targeting the golgi apparatus of synovial fibroblasts to attenuate rheumatoid arthritis","volume":"16","author":"Deng","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2026.118144_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107817","article-title":"TREX1 activators: a novel therapeutic strategy for rheumatoid arthritis management via cfDNA clearance","volume":"218","author":"Wang","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0725","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s42234-023-00138-x","article-title":"Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study","volume":"10","author":"Peterson","year":"2024","journal-title":"Bioelectronic Medicine"},{"issue":"9","key":"10.1016\/j.bcp.2026.118144_b0730","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1016\/S2665-9913(20)30172-7","article-title":"Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study","volume":"2","author":"Genovese","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0735","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/art.41516","article-title":"Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis","volume":"73","author":"Tao","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118144_b0740","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/adt.2007.089","article-title":"Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms","volume":"5","author":"Liang","year":"2007","journal-title":"Assay Drug Dev. Technol."},{"issue":"sup1","key":"10.1016\/j.bcp.2026.118144_b0745","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/1744666X.2015.1090312","article-title":"Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13)","volume":"11","author":"Kim","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.bcp.2026.118144_b0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2023.113436","article-title":"Drug-tolerant detection of anti-drug antibodies in an antigen-binding assay using europium chelate fluorescence","volume":"514","author":"van Strien","year":"2023","journal-title":"J. Immunol. Methods"},{"issue":"24","key":"10.1016\/j.bcp.2026.118144_b0755","doi-asserted-by":"crossref","first-page":"7477","DOI":"10.1007\/s00216-015-8915-8","article-title":"Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization","volume":"407","author":"Real-Fern\u00e1ndez","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0760","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/s41598-018-37950-4","article-title":"A surface plasmon resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies","volume":"9","author":"Beeg","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118144_b0765","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jim.2017.09.004","article-title":"Development and validation of a cell based assay for the detection of neutralizing antibodies against recombinant insulins","volume":"452","author":"Chatterjee","year":"2018","journal-title":"J. Immunol. Methods"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.118144_b0770","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","article-title":"Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF\u03b1 antagonists","volume":"373","author":"Lallemand","year":"2011","journal-title":"J. Immunol. Methods"},{"issue":"2","key":"10.1016\/j.bcp.2026.118144_b0775","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10067-018-4213-0","article-title":"Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA","volume":"38","author":"Ogri\u010d","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bcp.2026.118144_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2023.113575","article-title":"A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog","volume":"523","author":"Peek","year":"2023","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bcp.2026.118144_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118907","article-title":"The effects of drug transporters on the efficacy of methotrexate in the treatment of rheumatoid arthritis","volume":"268","author":"Gao","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2026.118144_b0790","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.774387","article-title":"Paeonol protects against methotrexate-induced nephrotoxicity via upregulation of P-gp expression and inhibition of TLR4\/NF-kappaB pathway","volume":"13","author":"Morsy","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118144_b0795","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3619320","article-title":"Methotrexate combined with 4-hydroperoxycyclophosphamide downregulates multidrug-resistance P-glycoprotein expression induced by methotrexate in rheumatoid arthritis fibroblast-like synoviocytes via the JAK2\/STAT3 pathway","volume":"2018","author":"Qin","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118144_b0800","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2007.070821","article-title":"Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis","volume":"67","author":"Tsujimura","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"48","key":"10.1016\/j.bcp.2026.118144_b0805","doi-asserted-by":"crossref","first-page":"30639","DOI":"10.1073\/pnas.2007935117","article-title":"Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells","volume":"117","author":"Hu","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2026.118144_b0810","article-title":"Gut dysbiosis is associated with difficult-to-treat rheumatoid arthritis","volume":"11","author":"Ruiz-Limon","year":"2024","journal-title":"Front. Med. (Lausanne)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118144_b0815","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-024-03432-4","article-title":"Obesity and fibromyalgia are associated with difficult-to-treat rheumatoid arthritis (D2T-RA) independent of age and gender","volume":"27","author":"Luciano","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2026.118144_b0820","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1456251","article-title":"Adherence to the antirheumatic drugs: a systematic review and meta-analysis","volume":"11","author":"Aksoy","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.bcp.2026.118144_b0825","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1049875","article-title":"Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems","volume":"9","author":"Watanabe","year":"2022","journal-title":"Front. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600479X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600479X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:37:54Z","timestamp":1783921074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522600479X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":165,"alternative-id":["S000629522600479X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118144","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/authorea.15003150\/v1","asserted-by":"object"}]},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress on drug resistance mechanisms and therapeutic strategies for difficult-to-treat rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118144"}}